Aprea expands IP protection for WEE1 and ATR programs; APR-1051 in Phase 1

Aprea said it expanded its patent estates for both its WEE1 and ATR inhibitor programs — the WEE1 family includes multiple pending U.S. and non-U.S. applications (2 pending U.S. apps, 1 U.S. provisional, 2 granted non-U.S., 12 pending non-U.S.) that, if granted, would expire in 2047, while the ATR estate includes 4 granted U.S. patents, additional pending U.S./international filings and 22 granted/13 pending non-U.S. patents with granted expirations of 2035–2037 and pending filings that could extend protection into 2045 (plus potential regulatory exclusivities). Clinically, APR-1051 (WEE1 inhibitor) is being evaluated in the ACESOT-1051 Phase 1 trial in biomarker-defined advanced/metastatic solid tumors; ATRN-119 had an RP2D of 1,100 mg QD from ABOYA-119 but the company closed that dose-escalation study in 2025 to focus resources on APR-1051 and is considering ATRN-119 combination approaches.